Importantly, we found that the novel Mcl-1 small molecular weight inhibitor VU661013 blocked Mcl-1 activity in ER+ breast cancer cells, increased caspase-mediated apoptosis in ER+ tumor cells, and when used in combination with ABT-263, produced robust killing of ERα+ tumor cells in culture and in vivo. Here, MCL1 is linked to breast carcinoma.